Surmounting antimicrobial resistance in the millennium superbug: Staphylococcus aureus

Central European Journal of Medicine

Volumn 5, Issue 1, 2010, Pages 6-11

  Saxena, Sanjai ^a   Gomber, Cham ^a  

^a THAPAR UNIVERSITY   (India)

Author keywords

Combinatorial biosynthesis; Enzymibiotics; MDR; MRSA; Rational drug design; S. Aureus; Vaccines

Indexed keywords

6 DEOXY 7 DIMETHYLAMINO 9 (N,N DIMETHYLGLYCINAMIDO) 6 NORTETRACYCLINE; AM 7359; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; CAB 175; CB 175; CEFAZOLIN PLUS IMIPENEM PLUS NETILMICIN PLUS VANCOMYCIN; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEPHALOSPORIN; DALBAVANCIN; DAPTOMYCIN; GARENOXACIN; GENTAMICIN; LINEZOLID; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; PTK 0796; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; RANBEZOLID; SITAFLOXACIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; WCK 771;

ANTIBIOTIC RESISTANCE; BACTERIAL ENDOCARDITIS; BACTERIAL SURVIVAL; CELL WALL; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; DIARRHEA; DNA DAMAGE; DRUG FORMULATION; DRUG STRUCTURE; DRUG TARGETING; HAND WASHING; HIGH THROUGHPUT SCREENING; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; SANITATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 77249138186     PISSN: 18951058     EISSN: 16443640     Source Type: Journal    
DOI: 10.2478/s11536-009-0132-4     Document Type: Review

References (164)

1. [1] Peacock S.J., de Silva I., Lowy F.D., What determines the nasal carriage of Staphylococcus aureus?, Trends Microbiol., 2001, 9, 605-610 (Pubitemid 33135417)
2. Pettit C.A., Fowler V.G., Staphylococcus aureus bacteremia and endocarditis, Cardiology Clinics, 2003, 21(2), 219-233
3. Fang G., Keys T.F., Gentry L.O., Harris A.A., Rivera N., Getz K. et al., Prosthetic valve endocarditis resulting from nosocomial bacteremia. A prospective, multicenter study, Ann. Intern. Med., 1993, 119(7), 560-567
4. Jevons, M.P., Celbenin-resistant staphylococci., Br. Med. J., 1961, 1, 124-125
5. Parker M.T., Hewitt J.H., Methicillin resistance in Staphylococcus aureus, Lancet, 1970, 1, 800-804
6. Ogston A., Micrococcus poisoning., J. Anal. Physiol., 1883, 17 24-58
7. Skinner D., Keefer CS., Significance of bacteremia caused by Staphylococcus aureus., Arch. Intern. Med., 1941, 68, 851-875
8. Archer G.L., Scott G., Conjugative transfer genes In Staphylococcal isolates from the United States, Antimicrob. Agents Chemother., 1991, 33, 2500-2504
9. Trucksis M., Hooper D.C., Wolfson J.S., Emerging resistance to Fluoroquinolones in Staphylococci, Ann. Intern. Med., 1991, 114, 424-426
10. Lacey R.W., Mitchell A.A.B., Gentamicin-resistant Staphylococcus aureus, Lancet, 1969, II, 1425-1426
11. Lowy F.D., Staphylococcus aureus infections, N. Engl.J. Med., 1998, 339, 520-532
12. Moellering R.C. Jr., Problems with antimicrobial resistance in gram-positive cocci, Clin. Infect. Dis., 1998, 26, 1177-1178
13. Lelievre H., Lina G., Jones M.E., Olive C., Forey F., Roussel-Delvallez M., et al., Emergence and Spread In French Hospitals of Methicillin-Reslstant Staphylococcus aureus with Increasing Susceptibility to Gentamicin and Other Antibiotics. J. Clin. Microbiol., 1999, 11, 3452-3457
14. Mulligan M.E., Ruane P.J., Johnston L., Wong P., Wheelock J.P., MacDonald K., et al. Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. Am. J. Med., 1987, 82(4A), 215-219
15. Harnett N., Brown S., Krishnan C., Emergence of Quinolone Resistance among Clinical Isolates of Methicillin-Resistant Staphylococcus aureus in Ontario, Canada, Antimicrob. Agents Chemother., 1991, 35(9), 1911-1913
16. Kuehnert M.J., Hill H.A., Kupronis B.A., Tokars J.I., Solomon S.L., Jernigan D.B., Methicillin-resistant Staphylococcus aureus-related hospitalizations, United States. Emerg.Infect. Dis., 2005, 11: 868-872
17. [17] Hiramatsu K., Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance, Lancet Infect. Dis., 2001, 1(3), 147-155 (Pubitemid 33586048)
18. Hiramatsu, K., Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan 1996, Morb. Mortal. Wkly. Rep., 1997, 27, 624-626
19. Centers for Disease Control and Prevention S. aureus resistant to Vancomycin in the US, Morb. Mortal. Wkly. Rep., 2002, 51, 565-567
20. Centers for Disease Control and Prevention, Vancomycin resistant S. aureus Pennysylvania 2002, Morb. Mortal. Wkly. Rep., 2002, 51, 902
21. Riley T.V., Pearman J.W., Rouse I.L., Changing epidemiologyofmethicillin- resistantStaphylococcus aureus in Western Australia, Med. J. Aust., 1995, 163, 412-414
22. Cookson B.D., Methicillin-resistant Staphylococcus aureus in the community: new battlefronts, or are the battles lost?, Infect. Control Hosp. Epidemiol., 2000, 21, 398-403
23. Chambers H.F., Community associated Methicillin resistant Staphylococcus aureus- resistance and virulence coverage. N. Engl. J. Med., 2005, 325, 1485-1487
24. [24] Moran G.J., Khshnadasan A., Gorwitz R.J. Fosheim G.E., McDougal L.K., Carey R.B. et al., Methicillin resistant S. aureus infections among patients in the emergency department, N. Engl. J Med., 2006, 355, 666-674 (Pubitemid 44244537)
25. Moreno F., Crisp F., Jorgenson J.H., Patterson and Patterson J. E., Methicillin-resistant Staphylococcus aureus as a community organism,Clin. Infect. Dis., 1995, 21, 1308-1312
26. Bukharle H.A., Abdelhadi M.S., Saeed I.A., Rubaish A.M., Larbi E.B., Emergence of methicillin-resistant Staphylococcus aureus as a community pathogen. Diagn.Microbiol.Infect.Dis., 2001, 40, 1-4
27. [27] Salgado C.D., Farr B.M., Calfee D.P., Community acquired methicillin-resistant Staphylococcus aureus: A meta-analysis of prevalence and risk factors, Clin.Infect. Dis., 2003, 36, 131-139 (Pubitemid 36143409)
28. [28] Adcock P.M., Pator P., Medly F., Patterson J.E., Murphy T.V., Methicillin- resistant Staphylococcus aureus in two child care centers, J. Infect. Dis., 1998, 178, 577-580 (Pubitemid 28347950)
29. [29] Lindenmayer J.M., Schoenfeld S.,O'Grady R., Carney J. K., Methicillin-resistant Staphylococcus aureus In a high school wrestling team and the surrounding community, Arch.Intern. Med., 1998, 158, 895-899 (Pubitemid 28183645)
30. Centers for Disease Control and Prevention. Outbreaks of community-associated methicillinresistant Staphylococcus aureus skin infections-Los Angeles County, California, 2002-2003, Morb. Mortal. Wkly. Rep., 2003, 52, 88
31. [31] Cohen P.R., Kurzrock R., Community-acquired methicillin-resistant Staphylococcus aureus skin infection: an emerging clinical problem, J. Am. Acad. Dermatol., 2004, 50, 277-280 (Pubitemid 38174291)
32. Olayinka B.O., Olnitola O.S., Olayinka A.T., Raji B., Antibiotic susceptibility pattern and multiple antibiotic resistance wider of S. aureus isolates in Zaria, Nigeria, J. Trop. Biosci., 2004, 451-454
33. Kowalski T.J., Berbari E.F., Osmon D.R., Epidemiology, treatment and prevention of community acquired methicillin resistant Staphylococcus aureus infections, Mayo Clin. Proc, 2005, 80(9), 1201-1208
34. [34] Francis J.S., Doherty M.C., Lopatin U., Johnston C.P., Sinha G., Ross T., Severe community onset pneumonia in healthy adults caused by methicillin resistant Staphylococcus aureus carrying panton valentine leukocidin genes, Clin. Infect. Dis., 2005, 40(1), 100-107 (Pubitemid 40053465)
35. O'Brien F.G., Pearman J.W., Gracey M., Riley T.V., Grubb W.B., Community strains of MRSA involved in hospital outbreak, J. Clin. Microbiol. 1999, 37(9), 2858-2862
36. Pelag A.Y. and Munckhof W.J., Fatal necrotizing pneumonias due to community acquired Methicillin resistant Staphylococcus aureus, Med. J. Aus., 2004, 181(4), 228-229
37. [37] Klevens M.R., Morrison A., Nadle J., Petit S., Gershman K., Ray S. et al., Invasive Methicillin resistant Staphylococcus aureus infections in the United States, JAMA, 2007, 298, 1763-1771 (Pubitemid 47598444)
38. [38] Fuda C., Suvorov M., Vakulenko S.B., Mobashrey S., The Basis for Resistance to β-Lactam antibiotics by Penicillin-binding Protein2a of Methicillinresistant Staphylococcus aureus, J. Biol. Chem., 2004, 279(39): 40802-40806 (Pubitemid 39287677)
39. Brown D.F.J., Reynolds P.E., Intrinsic resistance to beta-lactam antibiotics In Staphylococcus aureus. FEBS Lett, 1980, 122, 275-278
40. Hartman B.J., Tomasz, A., Low-affinity penicillin binding protein associated with β-lactam resistance In Staphylococcus aureus. J. Bacteriol., 1984, 58, 513-516
41. Georgopapadakou N.H., Dix B.A., Mauriz, Y.R., Possible physiological functions of penicillin-binding proteins in Staphylococcus aureus, Antimicrob. Agents Chemother., 1986; 29, 333-336
42. Utsui Y., Yokota T., Role of altered penicillin binding protein in methicillin and cepham resistant Staphylococcus aureus. Antimicrob. Agents Chemother., 1985, 28, 397-403
43. [43] Song M.D., Wachi M., Doi M., Ishino F., Matsuhashi M., .Evolution of inducible penicillin resistant target protein in methicillin resistant S. aureus by gene fusion, FEBS Lett., 1987, 221, 167-171 (Pubitemid 17124049)
44. [44] Walsh T.R., Howe R.A., The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus, Ann. Rev. Microbiol., 2002, 56, 657-675 (Pubitemid 35217470)
45. Chopra I., Antibiotic resistance in Staphylococcus aureus: Causes, concerns and cures?, Exp. Rev. Ant. Infect. Ther., 2003, 1(1), 45-55
46. Weisblum B., Erythromycin resistance by ribosome modification, Antimicrob. Agents Chemother., 1995, 39, 577-585
47. [47] Ross J.I., Eady E.A., Cove J.H., Canliffe W.J., Cunliffe W.J., Baumberg S., Wootton J.C., Inducible erythromycin resistance in Staphylococci is encoded by a member of ATP binding transport supergene family, Mol. Microbiol., 1990, 4, 1207-1214 (Pubitemid 120005382)
48. Saxena, S., Combating multidrug resistance microbes: A burgeoning problem In Microbes & Human Health, Vol.4, 2007; Edited by Dr. A.K.Chauhan, Dr.Harsha Kharkwal & Dr. Ajit Varma, pp.589-607, I. K. Internatlonal Publishing House, New Delhi, India ISBN81-89866-05-02
49. Bismuth R., Zilhao R., Sakamoto H. Guesdon J.L., Courvalin P., Gene heterogeneity for tetracycline resistance in Staphylococcus spp. Antimicrob. Agents Chemother., 1990, 34, 1611-1614
50. Warsa U.C., Nonoyama M., Ida T., Okamoto R., Okubo T., and Shimauchl C., et al., Detection of tet (K) and tet(M) in Staphylococcus aureus of Asian countries by Polymerase chain reaction, J. Antibiot, 1996, 49(11), 1127-1132
51. [51] Trzcinski K., Cooper B.S., Hryniewicz W., Dawson C.G., Expression of resistance to tetracyclines in strains of methicillin- resistant Staphylococcus aureus, J. Antimicrob. Chemother., 2000, 45, 763-770 (Pubitemid 30348944)
52. Schimtz, F.J., Angela K., Sadurski, R. , Milatovic D, Fluit A.C., et al. Resistance to tetracycline and distribution of tetracycline resistance genes In European Staphylococcus aureus isolates. J. Antimicrob. Chemother., 2001, 47, 239-240
53. Shinabarger D.L., Marotti K.R., Murray R.W., Lin A.H., Melchior E.P., Swaney S.M. et al. Mechanisms of actions of oxazlidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother., 1997, 41, 2132-2136
54. [54] Tsiodras S., Gold H.S., Sakouloulas G., Eliopoulos P.M., Wennersten C., Venkataraman L., et al., Linezolid resistance in a clinical isolate of Staphylococcus aureus, Lancet, 2001, 358, 207-208 (Pubitemid 32718546)
55. Kloss P., Xiong L., Shinabarger D.L., Mankin, A.S. Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center, J. Mol. Biol., 1999, 294(1), 93-101
56. [56] Vanuffel P., Giambattista Di M., Cocito, C., Chemical probing of virginiamycin M - promoted conformational change of the peptidyltransferase domain, Nuc. Acids Res., 1994, 22, 4449-4453 (Pubitemid 24336416)
57. Mitchell B.A., Brown M.H., Skurray, R.A., Qac A efflux pumps from Staphylococcus aureus: Comparative analysis of resistance to diamidines, biguanidines and guanylhydrazones, Antimicrob. Agents Chemother., 1998, 42, 475-571
58. [58] Walmsley M.B., Mckeegan K.S., Walmsley, A.R., Structure and function of efflux pumps that confer resistance to drugs, Biochem. J., 2003, 376, 313-338 (Pubitemid 38010517)
59. Allignet J., Solh N.E., Characterization of a new staphylococcal gene, vga B, encoding a putative ABC transfer conferring resistance to streptogramin A and related compounds, Gene, 1997, 202, 133-138
60. [60] Prunier A.L., Malbruny B., Laurans M., Brouard J., Duhamel J.F. and Leclercq R., High rate of macrolide resistance In Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains, J. Infect. Dis., 2003, 187, 1709-1716 (Pubitemid 36667881)
61. Trucksis M., Wolfson J.S., Hooper D.C., A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus, J Bact., 1991, 173(18), 5854-5860
62. [62] Ng, E.Y., Trucksis, M., Hooper, D.C., Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV Is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus, Antimicrob. Agents Chemother., 1996, 40, 1881-1888 (Pubitemid 26277810)
63. Allignet J., Loncle V., Simenel C., Delepierre M., El Solh N., Sequence of a staphylococcal gene, vat, encoding an acetyltransferase inactivating the A-type compounds of virglniamycln-like antibiotics, Gene, 1993, 130, 91-98
64. McGowan, J.E. Jr, Gerding D.N., Does antibiotic restriction prevent resistance?, New Horiz., 1996, 4: 370-376
65. Niederman M.S., Is "Crop rotation" of antibiotic the solution to a "resistant" problem to ICU?, Am. J. Resp. Crit. Care Med., 1997; 156: 1029-1031
66. Jarvis, W.R., Handwashing- the Semmelweis lesson forgotten?, Lancet , 1994, 344 (8933): 1311-1312
67. Casewell, M.W., Hill R.L., Minimal dose requirements for nasal mupirocin and its role in the control of epidemic MRSA., J. Hosp. Infect, 1991; 19: 35-40
68. Jones M.E., In vitro profile of a new β-lactam, Ceftobiprole with activity against MRSA., Clin. Microbiol. Infect, 2007, 13(2): 17-24
69. Koga T., Abe T., Harumi I., Takenouchi T., Kitayama A., Yoshida T., et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob. Agents Chemother., 2005, 49(8), 3239-3250
70. Sum P.E., Lee V.J., Testa RiT., Hlavka J.J., Ellestad G.A., et al. , Glycylcyclines - A new generation of potent antibacterial agents through modification of 9-aminotetracyclines, J. Med. Chem., 1994, 37, 184-188
71. Goldstein F.W., Kitzis M.D., Acar, J.F.N., N-Dimethylglycylamido derivatives of minocycline and 6-demethyl-6-desoxytetracycline. Two new glycylcyclines highly effective against tetracycline-resistant gram-positive cocci., Antimicrob. Agents Chemother., 1994, 38, 2218-2220
72. Livermore D.M., Tigecycline: what is it, and where should it be used?, J.Antimlcrob. Chemother., 2005, 56(4), 611-614
73. Bergeron J., Ammirati M., Danley D., Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet (M),-and Tet(O)mediated ribosomal protection, Antimicrob. Agents Chemother., 1996, 40, 2226-2228
74. Harris, R. and Cruz, M., Tigecycline (Tygacil): A Novel First-in-Class, Broad-Spectrum Intravenous Antibiotic For the Treatment of Serious Bacterial Infections, Pharmacy & Therapeutics, 31(1), 18-27and57
75. McKenney D., Quinn J.M., Jackson C.L., Guilmet J.L., Landry J.A., Tanaka S.K., et al. Evaluation of PTK 0796 in experimental model of Infections caused by gram positive and gram-negative pathogen. Abstr. InterSc. Conf. Antimicrob. Agents Chemother., 2003, Sep 14-17 , abstract no. F-757
76. Shah, P.M., The need for new therapeutic agents: what is in the pipeline?, Clinical Microbiol.Infect, 11, 36-42
77. Zeckel M.L., Preston D.A., Allen B.S., In vitro activities of AntiLY333328 and comparative agents against nosocomial gram positive pathogens collected in a 1997 global surveillance study, Antimicrob. Agents Chemother., 2000, 44(5), 1370-1468
78. Barrett J.F., Oritavanacin: Eli Lilly & Co., Curr. Opinion Investlg. Drugs, 2001, 2(8), 1039-1044
79. Jabés D., Candiani G., Romanó G., Brunati C., Riva S., and Cavaleri,M., Efficacy of Dalbavancin against Methicillin-Resistant Staphylococcus aureus in the Rat Granuloma Pouch Infection Model. Antimicrob. Agents Chemother., 48(4), 1118-1123
80. [80] Lin G., Credito K., Ednie L.M. and Appelbaum, P.C., Antistaphylococcal activity of Dalbvancin, an experimental glycopeptide, Antimicrob. Agents Chemother., 2005, 49(2), 770-772 (Pubitemid 40175692)
81. O'Hare M.D., Ghosh G., Felmingham D. and Grüeberg R.N., In vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial, J. Antimicrob.Chemother., 1990, 25, 217-220
82. Montecalvo M.A., Ramoplanin: a novel antimicrobial agent with the potential to prevent vancomycin-resistant enterococcal infection in high-risk patients, J. Antimicrob.Chemother., 2003, 51(Suppl. S3), iii31-iii35
83. Takahata M., Mitsuyama J., Yamashiro Y., Yonezawa M., Araki H., Todo Y., et al., In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone, Antimicrob. Agents Chemother., 1999, 43: 1077-1084
84. Noviello S., Ianniello F., Leone S. and Esposito S., Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens, J. Antimicrob. Chemother., 2003, 52, 869-872
85. Schmitz FJ, Fluit AC, Milatovic D, Verhoef J., Heinz H.P. and Brisse S., In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical Isolates of S.aureus, J. Antimicrob. Chemother., 2006, 46, 109-113
86. Bhagwat SS, Mundkar LA, Gupte SV, Patel M.V., and Khorakiwala H.F., The anti- MRSA quinolone WCK771 has potent activity against sequentially labeled mutants and has a narrow mutant selection windows against quinolone resistant S. aureus and preferentially targets DNA gyrase. Antimicrob. Agents Chemother., 2006, 50(11), 3568-3579
87. [87] Das B., Rudra S., Yadav A., Ray A., Raja Rao A.V.S., Shnivas A.S.S.V, et al., Synthesis and SAR of novel oxazolidinones: discovery of ranbezolid, Bioorg.Med.Chem.Lett, 2005, 15(19), 4261-4267 (Pubitemid 41187998)
88. Mathur T., Bhateja P., Pandya M., Fatma T., Rattan A., In vitro activity of RBx 7644(ranbezolid) on biofilm producing bacteria, Int.J. Antimicrob. Agents, 2004, 24(4), 369-373
89. Rattan A., RBx-7644: Oxazolidinone antibacterial, Drugs of the future, 2003, 28(11 ), 1070-1077
90. [90] Bush K., Macielag M. and Weidner-Wells, M., Taking inventory: antibacterial agents currently at or beyond Phase 1, Curr.Opin. Microbiol., 2004, 7(5), 466-476 (Pubitemid 39297126)
91. Gill C.J., Abruzzo G.K., Flattery A.M., Misura A.S., Bartizal K., Hickey E.J., In Vivo Efficacy of a Novel Oxazolidinone Compound in Two Mouse Models of Infection, Antimicrob. Agents Chemother., 2007, 51(9), 3434-3436
92. Yuan Z., Trias J.,White R.J., Deformylase as a novel antibacterial target, Drug Discovery Today, 2001, 6(18), 954-961
93. [93] Credito K, Lin G, Ednie LM and Appelbaum P.C., Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents, Antimicrob. Agents Chemother. 2004, 48, 4033-4036 (Pubitemid 39304642)
94. Hoang T.T., Schweizer H.P., Fatty acid biosynthesis in Pseudomonas aeruginosa: cloning and characterization of the fabAB operon encoding ß-hydroxydecanoyl-acyl carrier protein dehydratase (FabA) and ß-ketoacyl-acyl carrier protein synthase I (FabB). J Bacteriol., 1997, 179, 5326-5332
95. Heath R.J., Rubin J.R., Holland D.R., Zhang E., Snow M.E., and Rock C.O., Mechanism of Triclosan Inhibition of Bacterial Fatty Acid Synthesis, J. Biol. Chem. 1999, 274(16), 11110-11114
96. [96] Payne D.J., Warren P.V., Holmes D.J., Ji Y., Lonsdale J.T., Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery, Drug Discovery Today, 2001, 6(10), 537-544 (Pubitemid 32452153)
97. [97] Oh K.B., Oh M.N., Kim J.G., Shin D.S., Shin J, Inhibition of sortase-mediated Staphylococcus aureus adhesion to fibronectin via fibronectin-binding protein bysortase in hibitors, Appl. Microbiol. Biotechnol., 2005, 70(1 ), 102-106 (Pubitemid 43234535)
98. Kim S.H., Shin D.S., Oh M.N., Chung S.C., Lee J.S., Chang I.M., Oh K.B., Inhibition of Sortase, a Bacterial Surface Protein Anchoring Transpeptidase, by β-Sltosterol-3-O-glucopyranoside from Frltillarla vertlcillata, BioSci. Biotech. Blochem., 2003, 67(11): 2477-2479
99. Riedlinger J., Reicke A., Zähner H., Krismer B., Bull A.T., Maldonado L.A., Ward A.C., Goodfellow M., Bister B., Bischoff D.,Süssmuth R.D.,Fiedler H.P. , "Abyssomlcins, inhibitors of the paraamlnobenzoicacld pathway produced by the marine Verrucoslspora strain AB-18-032" J. Antibiot., 2004, 57, 271-279 (Pubitemid 38594465)
100. Allsop A.E., New Antibiotic discovery, novel screens, novel targets and Impact of genomics, Curr. Opin. Microbiol., 1998, 1(5), 530-534
101. Dunman PM, Murphy E, Haney S, Kellogg G.T. S., et al., Transcription Profiling-Based Identification of Staphylococcus aureus Genes Regulated by the agr and/or sarA Loci, J. Bacteriol. 2001, 183, 7341-7353 (Pubitemid 33121868)
102. Liu J., Dehbi M, Moeck G, Arhin F., Bauda P., Bergeron D., et al. , Antimicrobial drug discovery through bacteriophage genomics, Nature Biotech., 2004, 22(2), 185-191 (Pubitemid 38160533)
103. Moreillon P.,The efficacy of amoxicillin/clavulanate (Augmentin) in treatment of severe staphylococcal infections, J Chemother.1994, 6(2). 51-57
104. Prieto J, Aguilar L, Gimenez MJ, Toro D., GómezLus M. L., Dal-Ré R., et al. In vitro Activities of co-amoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroreslstant Staphylococcus aureus: a Controlled Study with vancomycin, Antimicrob. Agents Chemother.,1998, 42 (7), 1574-1577
105. Edouard R.S., Pestel-Caron M., Lemeland J.F., Caron F., In vitro synergistic effects of double and triple combinations of β-Lactams, vancomycin, and netilmicin against methlcillin-resistant Staphylococcus aureus strains, Antlmicrob. Agents Chemother., 2004, 44(11), 3055-3060
106. Shelburne S.A., Musher D.M., Hulten K.,Ceasar H., Lu M.Y., Bhaila I., etal. In vitro killing of communityassociated methlcillin-resistant Staphylococcus aureus with drug combinations, Antimicrob. Agents Chemother., 2004, 48, 4016-4019
107. Rand K.H. and Houck H., Synergy of daptomycin with oxacillin and other β-Lactamsagainst methicillin resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 2004, 48(8), 2871-2875 (Pubitemid 38989149)
108. Kono K., Tatara I., Takeda S., Arakawa K., Shirotani T., Okada M. et al. Antibacterial activity of epigallocatechin gallate methicillin resistant Staphylococcusaureus.JournalofJapanAssociation of Infectious Diseases, 1994, 68, 1518-1522
109. Shiota S., Shimizu M., MizushimaT, Ito H., Hatano T., Yoshida T., Tsuchiya T., Marked reduction in the minimum inhibitory concentration (MIC) of betalactams in methicillin-resistant Staphylococcus aureus produced by epicatechin gallate, an ingredient of green tea (Camellia sinensis)., Biol. Pharm. Bull., 1999, 22(12), 1388-1390
110. Takahashl O., Cai Z., Toda M., Hara Y., Shimamura T. et al., Appearance of antibacterial activity of oxacillin againt methicillin resistant Staphylococcus aureus (MRSA) in the presence of catechin. Journal of Japan Association of Infectious Diseases, 1995, 69: 1126-1134
111. Hamilton- Miller J.M, Shah S., Activity of tea component epicatechin gallate and analogues against methicillin resistant Staphylococcus aureus, J Antimicrob. Chemother., 2000, 46, 852-853 (Pubitemid 30843668)
112. Zhao W.H., Hu Z., Okubo S., Hara Y. and Shimamura T., Mechanism of synergy between epicatechin gallate and β-Lactams against methicllin resistant Staphylococcus aureus, Antimicrob. Agents Chemother., 2001, 45(6), 1737-1742 (Pubitemid 32466342)
113. Nicolson K., Evan G. and O' Toole P.W., Potentiation of methicllin activity against methicllin-resistant Staphylococcus aureus by diterpenes, FEMS Microbiol.Lett.,1999, 179(2), 233-239 (Pubitemid 29460683)
114. Smith E.C.J., Kaatz G.W., Seo S.M., Wareham N.,Williamson E.M. et al., The phenolic diterpene totarol inhibits multidrug efflux pump activity in S. aureus. Antimicrob. Agents Chemother., 2007, 51(12): 4480-4483
115. Schmitz F.J., Fluit A.C., Luckefahr M., Engler B., Hofmann B., Verhoef J. et al. The effect of reserplne, an inhibitor of multidrug efflux pumps, on the in vitro activities of ciprofloxacin, Sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus, J. Antimicrob. Chemother., 1998, 42, 807-810 (Pubitemid 29008084)
116. Gibbons S. and Udo E.E., The effect of reserpine, a modulator of multidrug efflux pumps on the in vitro activity of tetracycline against clinical isolates of methicillin resistant Staphylococcus aureus possessing tet(k) determinant, Phytother. Res., 2000, 74, 139-140 (Pubitemid 30168569)
117. Stermitz F.R., Lorenz P., Tawara J.N., Zenewicz L.A., Lewis K., Synergy in a medicinal plant: antimicrobial action of berbehne potentiated by 5-methoxyhydnocarpln, a multidrug pump inhibitor, Proc. Natl. Acad. Sci. USA, 2000, 97, 1433-1437
118. Stermitz F.R., Matsuda J.T., Lorenz P., MuellerP., ZenewlczL., Lewis K., et al., 5-Methoxy-hydnocarpln and pheophorblde A: Berberis species components which potentiate berberine growth inhibition of resistant Staphylococcus aureus. J. Nat. Prod., 2000, 63, 1146-1149
119. Oluwatuyl M., Kaatz G.W. and Gibbons S., Antibacterial and resistance modifying activity of Rosmarinus officinalis, Phytochem., 2004, 65(2) 3249-3254 (Pubitemid 39550392)
120. Fujita M., Shiota S., Kuroda T., Tsutomu H., Takashl Y., Tohru M., et al., Remarkable synergies between baicalein and tetracycline and baicalein and ß-Lactams against methicillin resistant Staphylococcus aureus, Microbiol. Immunol., 2005, 49, 391-396 (Pubitemid 40628500)
121. Khan I.A., Mirza Z.M., Kumar A., Verma V., Qazi G.N., Piperine, a phytochemlcal potentiator of ciprofloxacin against Staphylococcus aureus. Antimicrob. Agents Chemother., 2006, 50(2), 810-812
122. Smith P., Stewart J., Fyfe L., Influence of subinhibitory concentrations of plant essential oils on the production of enterotoxlns A and B and α-toxin by Staphylococcus aureus, J. Med. Microbiol., 2004, 53, 1023-1027 (Pubitemid 39391972)
123. Dickson R.A, Houghton P.J., Hylands P.J., Gibbons S., ; Antimicrobial, resistance-modifying effects, antioxidant and free radical scavenging activities of Mezoneuron benthamianum Baill, Securinega virosa Roxb. & Wild, and Microglossa pyrifolia Lam., Phytother. Res., 2006, 20, 41-45
124. Braga C., Leite A.A.M., Xavier K.G.S., Takahashi, J A., Bemquerer, M P., Chartone-Souza E., et al. Synergic interaction between pomegranate extract and antibiotics against Staphylococcus aureus, Can. J Microbiol., 2005, 51(7), 541-547 (Pubitemid 41719737)
125. Okusa P.N., Penge O., Devleeschouwer M., Duez P., Direct and indirect antimicrobial effects and antioxidant activity of Cordia gilletli De Wild (Boraginaceae), J. Ethnopharmacol., 2007, 112(3), 476-481 (Pubitemid 47016876)
126. Wright G.D., Resisting resistance: New chemical strategies for battling superbugs, Chem. Biol., 2000, 7, R127-32
127. Khstlansen J.E., The antimicrobial activity of psychotherapeutic drugs and stereo-isomeric analogues, Dan. Med. Bull., 1990, 37, 165-182 (Pubitemid 20151614)
128. Kristiansen J.E., Chlorpromazine: non-antibiotics with antimicrobial activity-new insights in managing resistance?, Curr.Opin.Investig. Drugs,1993, 2, 587-591
129. Kristlansen J.E., Amaral L., The potential management of resistant infections with nonantibiotics, J. Antimicrob. Chemother., 1997, 40, 319-327 (Pubitemid 27437949)
130. Kaatz G.W., Moudgal V.V., Seo S.M, Kristiansen J.E., Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus, Antimicrob. Agents Chemother., 2003, 47, 719-726
131. LAM K.S., Discovery of novel metabolites from marine actinomycetes, Curr. Opin. Microbiol. 2006, 9, 245-251 (Pubitemid 43817620)
132. Gomber C., Saxena S.. Anti-staphylococcal potential of Callistemon rigidus, Central European Journal of Medicine, 2007, 2(1), 79-88
133. Katarere D.R., Eloff J.N., Antibacterial and Antioxidant activity of Sutherlandia frutescens (Fabaceae) a reputed anti HIV/AIDS phytomedicine, Phytother. Res., 2005, 19(9), 779-781
134. Akinyemi K.O., Oladapo O., Okwara C.E., Ibe C.C. and Fasure K.A., Screening of crude extracts of six medicinal plants used in South-West Nigerian unorthodox medicine for anti-methicillin resistant Staphylococcus aureus activity, BMC Complementary and Alternative Medicine,2005, 5, 6 (doi:10.1186/1472-6882-5-6)
135. Nitta T., Arai T., Takamatsu H., Inatomi Y., Murata H., Iinuma M., Tanaka T., ItoT., Asai F., Ibrahim I., Nakanishi T. and Watabe K., Antibacterial Activity of Extracts Prepared from Tropical and Subtropical Plants on Methicillin-Resistant Staphylococcus aureus, Jour. Health Sciences,. 2002, 4, 273-276
136. Gibbons S., Anti-Staphylococcal plant natural products, Nat. Prod. Rep., 2004, 21, 263-277
137. Schempp C.M., Pelz K., Wittmer A., Schöpf E., Simon J.C., Antibacterial activity of hyperforin from St John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria, Lancet 1999, 353(9170), 2129
138. linuma M., Tosa H., Tanaka T., Asai F., Kobayashi Y., Shimano R., Miyauchi K., Antibacterial activity of Xanthones from guttiferous plants against Methicillin resistant Staphylococcus aureus, J. Pharm. Pharmacol., 1996, 48(8), 861-865
139. Keller M. and Zengler K. Tapping into microbial diversity, Nature Rev. Microb. 2004, 2(2),141-150.
140. Demain A.L, Microbial natural products: Alive and well in 1998, Nature Biotechnol, 1998, 16, 3-4
141. Demain A.L., Pharmacologically active secondary metabolites of microorganisms, Appl. Microbiol. Biotechnol., 1999, 52, 455-463
142. Tulp M. and Bohlin L. Functional versus chemical diversity: is biodiversity important for drug discovery?, Trends Pharmacol. Sci., 2002, 23, 225-231
143. Wang J., Soisson S.M.,Young K., Shoop W., Kodali S., Galgoci A., Painter R.,et al., Platensimycin is a selective Fab F inhibitor with potent antibiotic properties, Nature, 2006, 441: 358-361
144. Bull A.T., Stach J.E., Ward A.C., Goodfellow M., Marine actinobacteria: Perspectives, challenges, future directions, Antonie Van Leeuwenhoek, 2005, 87, 65-79
145. Strobel G. and Daisy B., Bioprospecting for microbial endophytes and their natural products, Microb. Mol.Biol. Rev. 2003, 67(4), 491-502 (Pubitemid 37549769)
146. Castillo U., Strobel G.A., Ford E.J., Hess W.M., Porter H., Jensen J.B., et.al., Munumbicins, widespectrum antibiotics produced by Streptomyces NRRL 30562, endophytic on Kennedia nigricans, Microbiol., 2002, 148, 2675-2685
147. Lee L.Y, Miyamoto Y.J., Mclntyre B.W., Hook M., McCrea K.W., McDevitt D., Brown E.L., The Staphylococcus Map Protein is an immmunomodulator that interferes with T-cell mediated responses, J. Clin. Invest, 2002, 110, 1461-1471 (Pubitemid 35396917)
148. Shinefield H., Black S., Fattom A., Horwith G., Rasgon S., Ordonez J.,et al., Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis, N. Engl. J. Med., 2002, 346, 491-496
149. Burnie J.P., Matthews R.C., Carter T., Beaulieu E., Donohoe M., Chapman C., Williamson P. and Hodgetts S.J., Identification of an Immunodominant ABC Transporter in Methicllin-Resistant Staphylococcus aureus Infections, Infect. Immun., 2000, 68(6), 3200-3209 (Pubitemid 30340410)
150. Schuhardt V.T., Schindler C.A., Lysostaphin therapy in mice infected with Staphylococcus aureus., J Bacteriol., 1964, 88, 815-816
151. Kusuma C.M., Kokai-Kun J.F., Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of Staphylococcus aureus, Antimicrob. Agents Chemother., 2005, 49, 3256-3263
152. Kokai-Kun J.F., Walsh S.M., Chanturiya T., Mond J.J., Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob. Agents Chemother., 2003, 47(5), 1589-1597
153. Yang X., Cong-Ran L., Ren-Hui L., Wang Y.M., Zhang W.X., Chen H.Z., et al., In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China Journal of Medical Microbiology, 2007, 56, 71-76
154. Kiri N., Gordon A., Climo M.W., Combinations of Lysostaphin with β-Lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis, Antimicrob.Agents Chemother., 2002, 46(6), 2017-2020 (Pubitemid 34535236)
155. Vavra S.B., Roberta B.C., Roberts.D.,Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate, J. Antimicrob. Chemother., 2001, 48, 617-625 (Pubitemid 33100307)
156. Stranden A., Ehlert K., Labischinski H., BergerBachi B., Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a fem AB null mutant of methicillin-resistant Staphylococcus aureus.J. Bacteriol., 1997, 179, 9-16
157. Ling B. and Berger-Bachi, B., Increased overall antibiotic susceptibility in Staphylococcus aureus femAB null mutants. Antimicrob. Agents Chemother., 1998, 42, 936-938
158. Schneider M.M.S., Berger-Bächi B., Tossi A., Sahl A.G., Wiedemann I., In vitro assembly of a complete, pentaglycine interpeptide bridge containing cell wall precursor (lipid II-Gly5) of Staphylococcus aureus, Mol. Microbiol., 2004, 53(2), 675-685
159. Hutchinson C.R., Combinatorial biosynthesis for new drug discovery, Curr.Opin Microb.,1998, 1, 319-329 (Pubitemid 128430237)
160. Borchardt J.K., Genetic engineering may keep one of the richest drug gold mines from being played out, Modern Drug Discovery, 1999, 2(4), 22-29
161. Jacobsen J.R., Khosla C., New directions in metabolic engineering.,Curr.Opin. Chem. Biol., 1998, 2, 133-137
162. Saxena, S. and Kumar D., Human pathogenic bacteria-plant interaction: Potential as novel antimicrobials, International Journal of Biomedical and Pharmaceutical Sciences, 2007, 1(2), 120-123
163. Baltz R.H., Vivian M. Stephen K.W., Natural products to drugs: daptomycin and related lipopeptide antibiotics, Nat. Prod. Rep., 2005, 22, 717-727
164. Yin X, Zabriskie TM., The enduracidin biosynthetic gene cluster from Streptomyces fungicidicus, Microbiol., 2006, 152, 2969-2983 (Pubitemid 44542378)